Claudio A Schioppa

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 6

Top Topics

Clinical Practice

Epidermal Growth Factor Receptor

Top Venues

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Petros Christopoulos, Nicolas Girard, Claudia Proto, Marta Soares, Pilar Garrido Lopez, Anthonie J van der Wekken, Sanjay Popat, Joris Diels, Claudio A Schioppa, Jan Sermon, Nora Rahhali, Corinna Pick-Lauer, Agnieszka Adamczyk, James Penton, Marie Wislez
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations. Cancers 15 (22) (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)